Can we use serum Anti-Mullerian hormone to differentiate the diagnosis between polycystic ovary syndrome patients and healthy women with polycystic ovarian morphology and regular menstrual cycles

References

1. ↵
   1. Yildiz BO,
   2. Bozdag G,
   3. Yapici Z,
   4. Esinler I,
   5. Yarali H

   (2012) Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 27:3067–3073.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group

   (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. National Institute of Health

   Evidence-based methodology workshop on polycystic ovary syndrome, Available at: http://prevention.nih.gov/docs/programs/pcos/FinalReport.pdf. [Updated 2012; Accessed 2014 March].
4. ↵
   1. Dewailly D,
   2. Lujan ME,
   3. Carmina E,
   4. Edars MI,
   5. Laven J,
   6. Norman RJ,
   7. et al.

   (2014) Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 20:334–352.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Duijkers IJM,
   2. Klipping C

   (2010) Polycystic ovaries, as defined by the 2003 Rotterdam consensus criteria, are found to be very common in young healthy women. Gynecol Endocrinol 26:152–160.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Catteau-Jonard S,
   2. Bancquart J,
   3. Poncelet E,
   4. Lefebvre-Maunoury C,
   5. Robin G,
   6. Dewailly D

   (2012) Polycystic ovaries at ultrasound: normal variant or silent polycystic ovary syndrome? Ultrasound Obstet Gynecol 40:223–229.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Kruszyńska A,
   2. Słowińska-Srzednicka J

   (2017) Anti-Müllerian hormone (AMH) as a good predictor of time of menopause. Prz Menopauzalny 16:47–50.

   OpenUrl
8. ↵
   1. Sahmay S,
   2. Atakul N,
   3. Oncul M,
   4. Tuten A,
   5. Aydogan B,
   6. Seyisoglu H

   (2013) Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 170:157–161.

   OpenUrlCrossRefPubMed
9. ↵
   1. Tremellen K,
   2. Zander-Fox

   (2015) Serum anti-Mullerian hormone assessment of ovarian reserve and polycystic ovary syndrome status over the reproductive lifespan. Aust N Z J Obstet Gynaecol 55:384–389.

   OpenUrl
10. ↵
    1. Lie Fong S,
    2. Schipper I,
    3. Valkenburg O,
    4. de Jong FH,
    5. Visser JA,
    6. Laven JS

    (2015) The role of anti-Mullerian hormone in the classification of anovulatory infertility. Eur J Obstet Gynecol Reprod Biol 186:75–79.

    OpenUrl
11. ↵
    1. Iliodromiti S,
    2. Kelsey TW,
    3. Anderson RA,
    4. Nelson SM

    (2013) Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome?A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab 8:3332–3340.

    OpenUrl
12. ↵
    1. Sahmay S,
    2. Aydin Y,
    3. Oncul M,
    4. Senturk LM

    (2014) Diagnosis of polycystic ovary syndrome: AMH in combination with clinical symptoms. J Assist Reprod Genet 31:213–220.

    OpenUrl
13. ↵
    1. Pinola P,
    2. Morin-Papunen LC,
    3. Bloigu A,
    4. Puukka K,
    5. Ruokonen A,
    6. Järvelin MR,
    7. et al.

    (2014) Anti-Mullerian hormone: correlation with testosterone and oligo- or amenorrhoea in female adolescence in a population-based cohort study. Hum Reprod 29:2317–2325.

    OpenUrlCrossRefPubMed
14. ↵
    1. Lauritsen MP,
    2. Bentzen JG,
    3. Pinborg A,
    4. Loft A,
    5. Forman JL,
    6. Thuesen LL,
    7. et al.

    (2014) The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod 29:791–801.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    1. Sathyapalan T,
    2. Al-Qaissi A,
    3. Kilpatrick ES,
    4. Dargham SR,
    5. Atkin SL

    (2018) Anti-Mullerian hormone measurement for the diagnosis of polycystic ovary syndrome. Clin Endocrinol (Oxf) 88:258–262.

    OpenUrl
16. ↵
    1. Faul F,
    2. Erdfelder E,
    3. Buchner A,
    4. Lang AG

    (2009) Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 41:1149–1160.

    OpenUrlCrossRefPubMedWeb of Science
17. ↵
    1. Cohen J

    (1988) Statistical power analysis for the behavioral sciences (Lawrence Erlbaum, Hillsdale (NJ)), 2nd ed.
18. ↵
    1. Song DK,
    2. Oh LY,
    3. Lee H,
    4. Sung Y

    (2017) Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an Anti-Mullerian hormone cutoff value. Korean J Intern Med 32:690–698.

    OpenUrl
19. ↵
    1. Sahmay S,
    2. Atakul N,
    3. Aydogan B,
    4. Aydin Y,
    5. Imamoglu M,
    6. Seyisoglu H

    (2013) Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome. Acta Obstet Gynecol Scand 92:1369–1374.

    OpenUrlCrossRefPubMed
20. ↵
    1. Quinn M,
    2. Kao C,
    3. Ahmad AK,
    4. Cedars M,
    5. Santoro N,
    6. Eisenberg E,
    7. et al.

    (2016) Anti-Mullerian hormone (AMH) as a predictor of polycystic ovary syndrome (PCOS): age and body mass index (BMI)-stratified thresholds for distinguishing PCOS from controls using an identical assay. Fertil Steril (Suppl 106):250.
21. ↵
    1. Sathyapalan T,
    2. Al-Qaissi A,
    3. Kilpatrick ES,
    4. Dargham SR,
    5. Atkin SL

    (2018) Anti-Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome. Clin Endocrinol (Oxf) 88:258–262.

    OpenUrl
22. ↵
    1. Broer SL,
    2. Broekmans FJ,
    3. Laven JS,
    4. et al.

    (2014) Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update 20:688–701.

    OpenUrlCrossRefPubMedWeb of Science
23. ↵
    1. Ozcan P,
    2. Ficicioglu C,
    3. Yeşiladali M,
    4. Devranoğlu B,
    5. Aydın S,
    6. Batmaz G

    (2016) Age-related distribution of basal Anti-Mullerian hormone levels in a population of infertile women. Clin Anal Med 7:355–358.

    OpenUrl
24. ↵
    1. Tokmak A,
    2. Kokanali D,
    3. Timur H,
    4. Kuntay Kokanali M,
    5. Yilmaz N

    (2016) Association between anti-Mullerian hormone and insulin resistance in non-obese adolescent females with polycystic ovary syndrome. Gynecol Endocrinol 32:926–930.

    OpenUrl
25. ↵
    1. Sahmay S,
    2. Aydogan Mathyk B,
    3. Sofiyeva N,
    4. Atakul N,
    5. Azemi A,
    6. et al.

    (2018) Serum AMH levels and insulin resistance in women with PCOS. Eur J Obstet Gynecol Reprod Biol 224:159–164.

    OpenUrl
26. ↵
    1. Gang D,
    2. Tal R

    (2016) The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reproductive Biomedicine Online 33:15–28.

    OpenUrlCrossRef
27. ↵
    1. Sahmay S,
    2. Aydın Y,
    3. Atakul N,
    4. Aydogan B,
    5. Kaleli S

    (2013) Relation of antimullerian hormone with the clinical signs of hyperandrogenism and polycystic ovary morphology. Gynecological Endocrinology 30:130–134.

    OpenUrl
28. ↵
    1. Dewailly D,
    2. Robin G,
    3. Peigne M,
    4. Decanter C,
    5. Pigny P,
    6. Catteau,
    7. et al.

    (2016) Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary. Hum Reprod Update 22:709–724.

    OpenUrlCrossRefPubMed
29. ↵
    1. Simões-Pereira J,
    2. Nunes J,
    3. Aguiar A,
    4. Sousa S,
    5. Rodrigues C,
    6. Sampaio Matias J,
    7. et al.

    (2018) Influence of body mass index in anti-Müllerian hormone levels in 951 non-polycystic ovarian syndrome women followed at a reproductive medicine unit. Endocrine 61:144–148.

    OpenUrl
30. 1. Moy V,
    2. Jindal S,
    3. Lieman H,
    4. Buyuk E

    (2015) Obesity adversely affects serum anti-müllerian hormone (AMH) levels in Caucasian women. J Assist Reprod Genet 32:1305–1311.

    OpenUrlCrossRefPubMed
31. ↵
    1. Sahmay S,
    2. Usta T,
    3. Erel CT,
    4. Imamoglu M,
    5. Kucuk M,
    6. Atakul N,
    7. et al.

    (2012) Is there any correlation between amh and obesity in premenopausal women? Arch Gynecol Obstet 286:661–665.

    OpenUrlCrossRefPubMed
32. ↵
    1. Robker RL,
    2. Akison LK,
    3. Bennett BD,
    4. Thrupp PN,
    5. Chura LR,
    6. Russell DL,
    7. et al.

    (2009) Obese women exhibit differences in ovarian metabolites, hormones, and gene expression compared with moderate-weight women. J Clin Endocrinol Metab 94:1533–1540.

    OpenUrlCrossRefPubMedWeb of Science
33. ↵
    1. Robker RL,
    2. Wu LL,
    3. Yang X

    (2011) Inflammatory pathways linking obesity and ovarian dysfunction. J Reprod Immunol 88:142–148.

    OpenUrlCrossRefPubMedWeb of Science
34. ↵
    1. Practice Committee of American Society for Reproductive Medicine

    (2013) Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil Steril 99:63.

    OpenUrlCrossRefPubMed